Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects

dc.creatorGonçalves, Heitor de Sá
dc.creatorPontes, Maria Araci de Andrade
dc.creatorBührer-Sékula, Samira
dc.creatorCruz, Rossilene
dc.creatorAlmeida, Paulo Cesar
dc.creatorMoraes, Maria Elisabete Amaral de
dc.creatorPenna, Gerson Oliveira
dc.date2020-05-21T13:16:52Z
dc.date2020-05-21T13:16:52Z
dc.date2012
dc.date.accessioned2023-09-26T20:35:59Z
dc.date.available2023-09-26T20:35:59Z
dc.identifierGONCALVES, Heitor de Sá et al . Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 107, p. 74-78, dec. 2012. Supl. 1.
dc.identifier0074-0276
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/41338
dc.identifier10.1590/s0074-02762012000900013
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8860331
dc.descriptionGerson Oliveira Penna - Fundação Oswaldo Cruz. Fiocruz Brasília. Brasília, DF, Brasil. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento.
dc.descriptionColaboradores: Marcelo Távora Mira (PUC-Paraná); Dra. Maria Lúcia Fernandes Penna (UFF) e Dra. Sinésio Talhari (UNL-AM).
dc.descriptionDECIT-MS/CNPq
dc.descriptionThis study sought to verify the correlation between leprosy types and the adverse effects of treatment drugs. This quantitative, prospective, nested study was developed at the Dona Libânia Dermatology Centre in Fortaleza, Brazil. Data were collected from November 2007-November 2008. During this period, 818 leprosy patients were diagnosed and began treatment. Forty patients with tuberculoid leprosy (TT) were selected. Twenty patients followed a standard therapy of dapsone and rifampicin and 20 were administered dapsone, rifampicin and clofazimine (U-MDT). Twenty patients with borderline lepromatous (BL) and lepromatous leprosy (LL) were also selected and treated with U-MDT. All of the subjects received six doses. With the exception of haemolytic anaemia, there was a low incidence of adverse effects in all the groups. We did not observe any differences in the incidence of haemolytic anaemia or other side effects across groups of patients with TT, BL or LL treated with U-MDT.
dc.formatapplication/pdf
dc.languageeng
dc.publisherInstituto Oswaldo Cruz
dc.rightsopen access
dc.subjectClofazimine
dc.subjectDapsone
dc.subjectDrug Therapy, Combination
dc.subjectLeprostatic Agents
dc.subjectLeprosy, Lepromatous
dc.subjectLeprosy, Multibacillary
dc.subjectLeprosy, Tuberculoid
dc.subjectProspective Studies
dc.subjectRifampin
dc.subjectLeprosy
dc.subjectMultibacillary leprosy
dc.subjectPaucibacillary leprosy
dc.subjectAdverse effects
dc.subjectTherapeutics
dc.subjectLeprostatic agents
dc.subjectHanseníase
dc.subjectMycobacterium leprae
dc.subjectHansenostáticos
dc.subjectDoenças Transmissíveis
dc.subjectProgressão da Doença
dc.subjectHanseníase Multibacilar
dc.subjectHanseníase Paucibacilar
dc.titleBrazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects
dc.typeArticle


Este ítem pertenece a la siguiente institución